Emergent BioSolutions Wins $24M BARDA Contract for Anthrax Vaccine CYFENDUS
EBS sits 40% above its 52-week low of $4.36.
Summary
Emergent BioSolutions secured a $24 million contract modification from BARDA to supply its CYFENDUS anthrax vaccine. This is a new government award, distinct from the $52.7 million ACAM2000 modification in June and the $21.5 million BioThrax order earlier this year. The deal reinforces Emergent's role in U.S. biodefense preparedness and adds to its government contract backlog. The company recently announced a restructuring to save $40 million amid wider Q2 losses, so this award provides a modest revenue boost. The contract is funded under an existing HHS contract, and delivery timing is not specified.
At the time of this announcement, EBS was trading at $6.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $312.8M. The 52-week trading range was $4.36 to $14.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.